Chargement en cours...
Mechanisms of resistance to ErbB-targeted cancer therapeutics
The ErbB receptors, such as EGFR, have been intensely pursued as targets for cancer therapeutics. However, a large percentage of patients who are initially responsive to ErbB-targeted therapies experience tumor recurrence and become refractory to therapy. In this issue of the JCI, Guix et al. demons...
Enregistré dans:
Auteurs principaux: | , |
---|---|
Format: | Artigo |
Langue: | Inglês |
Publié: |
American Society for Clinical Investigation
2008
|
Sujets: | |
Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2430503/ https://ncbi.nlm.nih.gov/pubmed/18568082 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI36260 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|